Loading...
Metabolic Peptide Demand And New Capacity Will Support Stronger Long Term Earnings Potential
AN
AnalystHighTarget
Not Invested
Community Contributor
Published
09 Jan 26
Views
7
09 Jan
CHF 36.40
AnalystHighTarget's Fair Value
CHF 43.88
17.1% undervalued intrinsic discount1Y
70.1%7D
-4.0%1Y
70.1%7D
-4.0%You can edit this narrative until Jan 10 10:05 PM. Then, changes will post as Updates.
Author's Valuation
CHF 43.8817.1% undervalued intrinsic discount
AnalystHighTarget Fair Value